Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Terminated 3Completed 1

Sponsor Class

OTHER 12NETWORK 4INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Breast 2Other hematologic neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Classical hematology 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × lonafarnib × Clear all
NCT00050336 2015-08-27

Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 3 Terminated
702 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00109538 2015-05-01

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 3 Terminated
47 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00081510 2015-04-15

Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Merck Sharp & Dohme LLC

Phase 2 Completed
110 enrolled
Breast

Breast Neoplasms

NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
5 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡